Dok-7 Protein Modulates MuSK Activity for Neuromuscular Junction Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mechanism activated by muscle-specific tyrosine kinase (MuSK) is not well understood, and there is a need to modulate its activity to address neuromuscular junction disorders.
Innovation Solution
A DNA encoding a polypeptide, specifically the Dok-7 protein, which belongs to the Dok family of intracellular signal transduction proteins, is used to modulate MuSK activity. This involves a nucleotide sequence with substitutions, deletions, or additions of amino acid residues, and a vector is introduced into cells to produce the polypeptide, which can be used in pharmaceutical compositions or to screen for therapeutic drugs for neuromuscular junction diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If agrin is secreted by motor nerve endings to activate MuSK, then MuSK activity is enhanced and AChR clustering is promoted, but the mechanism becomes dependent on nerve-derived factors and cannot explain early muscle-intrinsic AChR clustering
Solution Approach 1:
The patent identifies Dok-7 as an intermediary protein that mediates between MuSK and other signaling components. Dok-7 acts as a scaffolding protein that brings together MuSK, phosphatidylinositol 3-kinase (PI3K), and other signaling molecules, enabling MuSK activation and AChR clustering to proceed through a defined molecular pathway that can operate independently of agrin in certain contexts
Solution Approach 2:
The patent demonstrates that muscle cells possess intrinsic capability to activate MuSK and cluster AChR through self-organized signaling pathways. The identification of muscle-expressed proteins like Dok-7 and their ability to interact with MuSK shows that the muscle can autonomously initiate and maintain AChR clustering without continuous dependence on nerve-derived agrin, particularly during early development
2Reliability
If MuSK activation is prerequisite for AChR clustering, then neuromuscular junction formation is ensured, but the detailed signaling mechanism remains unclear and difficult to target therapeutically
Solution Approach 1:
The patent segments the MuSK signaling pathway into distinct functional modules: Dok-7 as a scaffolding component, PI3K as a kinase component, and downstream effectors. This segmentation allows each component to be studied and targeted independently, providing therapeutic avenues for neuromuscular disorders without requiring complete understanding of the entire pathway
Solution Approach 2:
The patent identifies specific molecular parameters within the MuSK signaling pathway, such as the presence and conformation of Dok-7, phosphorylation states of MuSK, and activation levels of PI3K. These parameter changes can be measured and targeted therapeutically, converting the abstract concept of 'MuSK activation' into quantifiable, druggable parameters
3Productivity
If high-density AChR clusters are formed in postsynaptic region, then neuromuscular transmission efficiency is improved, but neuromuscular transmission disorders occur when clustering is defective
Solution Approach 1:
The patent identifies early molecular events in the MuSK signaling pathway, such as Dok-7 binding to MuSK and recruitment of PI3K, as potential intervention points. By targeting these upstream events, therapeutic strategies can prevent the development of neuromuscular transmission disorders before they manifest as functional deficits, cushioning against future transmission failures
Solution Approach 2:
The patent describes feedback mechanisms within the MuSK signaling pathway, where activated MuSK phosphorylates downstream targets that can regulate MuSK activity itself. Understanding these feedback loops allows for development of therapeutic agents that can restore balanced signaling in diseased states, maintaining both transmission efficiency and stability
Data Source
Figure 1~2
Figure 3
Figure 4~5
AI summary
Disclosed are DNA encoding a polypeptide which can modulate the activity of a muscle-specific tyrosine kinase, and others. The DNA is selected from the following members (a) to (d): (a) DNA comprising a specific nucleotide sequence; (b) DNA comprising a nucleotide sequence capable of hybridizing with a specific nucleotide sequence under stringent conditions; (c) DNA comprising a nucleotide sequence encoding an amino acid sequence having the substitution, deletion and/or addition of one or several amino acid residues in a specific amino acid sequence; and (d) DNA comprising a nucleotide sequence having 90% or higher homology to a specific nucleotide sequence.